1. Bahn RS, Heufelder AE. Pathogenesis of Graves’ Ophthalmopathy. N Engl J Med 1993; 329(20): 1468-75
2. Garrity JA, Bahn RS. Pathogenesis of Graves’ Ophthalmopathy: Implications for Prediction, Prevention and Treatment. Am J Ophthalmol 2006; 142(1): 147-153
3. Rootman J, Dolman PJ. Thyroid Orbitopathy (Chapter eight) in: Diseases of the Orbit. A Multidisciplinary Approach. Hagerstown: Lippincott Williams & Wilings, 2003
4. Gerding MN, Terwee CB, Dekker FW et al. Quality of life in patients with Graves’ Ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 1997; 7(6): 885-889
5. Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994; 92: 477-588
6. Kendall-Taylor P, Perros P. Clinical presentation of thyroid associated orbitopathy. Thyroid 1998; 8:427-428
7. Burch HB, Wartofsky L. Graves’ Ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14: 747-793
8. Fatourechi V, Pajouhi M, Fransway AF: Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine (Baltimore) 1994 Jan; 73(1): 1-7
9. Perros P, Kendall-Taylor P. Natural history of thyroid eye disease. Thyroid 1998; 8: 423-425
10. Bartalena L, Marcocci C, Bogazzi F et al. Relation between therapy for hyperthyroidism and the course of Graves Ophthalmopathy. N Engl J Med 1998; 338: 73-78
11. Dolman PJ, Rootman J. Predictors of disease severity in thyroid-related orbitopathy. (chap18) Orbital Disease. Present status and future challenges. Taylor and Francis, 2005
12. Prummel MF, Wiersinga WM. Smoking and risk of Graves’ disease. JAMA 1993; 269: 479-482
13. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 1996; 45: 477-481
14. Cruz AA, Akaishi PM, Vargas MA et al. Association Between Thyroid Autoimmune Dysfunction and Non-Thyroid Autoimmune Diseases. Ophthalmic Plastic & Reconstr Surg 2007; 23(2):104-108
15. Pritchard J, Horst N, Cruikshank W et al. Igs from patients with Graves’ disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 2002; 168: 942-950
16. Pritchard J, Han R, Horst N et al. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor 1 receptor pathway. J Immunol 2003; 170: 6348-6354
17. Rundle FF. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci 1945; 5:177-194
18. Rundle FF. Ocular changes in Graves’ disease. QJM 1960; 29: 113-126
19. Selva D, Chen C, King G. Late reactivation of thyroid orbitopathy. Clin & Exp Ophthalmol 2004; 32 (1), 46–50
20. Werner, SC. Classification of the eye changes of Graves’ disease. American J Ophthalmology 1969; 68:646-648
21. Mourits MP, Prummel MF, Wiersinga WM et al. Clinical activity score as a guide in the management of patients with Graves’ Ophthalmopathy. Clin Endocrinol 1997; 47: 9
22. Dolman PJ, Rootman J. VISA Classification for Graves’ Orbitopathy. Ophthal Plast Reconstr Surg. 2006; 22(5):319-24.
23. Beckendorf V, Maalouf T, George J-L et al. Place of radiotherapy in the treatment of Graves’ orbitopathy. Int J Radiation Oncology Biol Phys 1999; 43: 805-15
24. Viebahn M, Marricks ME, Osterloh MD. Synergism between diabetic and radiation retinopathy: a case report and review. Br J Ophthalmol 1991; 75:29-32
25. Cockerham KP, Mourits MPh, McNab AA et al. Does radiotherapy have a role in the management of thyroid orbitopathy? Debate. Br J Ophthalmol 2002; 86: 102-104
26. Kahaly G, Schrezenmeir J, Krause U et al. Ciclosporin and prednisone vs prednisone in treatment of Graves’ Ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986; 16(5): 415-422
27. Bartalena L, Marcocci C, Chiovato L et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves’ Ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56(6): 1139-1144
28. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61: 883-888
29. Gerling J, Lieb B, Kommerell G. Duction ranges in normal probands and patients with Graves’ ophthalmopathy, determined using the Goldmann perimeter. Int Ophthalmol. 1998; 21(4): 213-21
30. Dolman PJ, Kendler D, Rootman J. Measuring ocular excursions in Graves’ Orbitopathy. (Abst) International Congress of Ophthalmology 2004
